

ESR1m Educational Webinar: Integrating ESR1m Testing into HR+/HER2– Metastatic Breast Cancer Care

Dear [First Name Last Name],

On behalf of AstraZeneca International Medical Oncology team, we are pleased to invite you to the **ESR1m Educational Webinar: Integrating ESR1m Testing into HR+/HER2– Metastatic Breast Cancer** Care, taking place on **3rd September**, from **13:00–14:30 BRT (20:00 – 21:30 GST)** on **Zoom**.



3rd September
2026



13:00 – 14:30
BRT (Brazil)



Virtual
(Zoom)

As the understanding of **ESR1 mutations (ESR1m)** continues to evolve, integrating molecular testing into clinical decision-making is becoming increasingly important in the management of **HR+/HER2– metastatic breast cancer**.

This educational webinar aims to provide practical insights into current evidence, testing approaches, and real-world considerations for implementing *ESR1m* testing in routine practice.

Meeting Objectives:

- Review the evolving evidence on *ESR1* mutation (*ESR1m*) in HR+/HER2- metastatic breast cancer management, including how molecular progression and resistance biology are relevant to disease management.
- Discuss practical considerations for *ESR1m* testing in HR+/HER2- metastatic breast cancer, including key technical aspects of detection, pre-analytical and logistical factors, interpretation and reporting, and current challenges and solutions associated with ctDNA testing.
- Optimize evidence-based approaches for integrating *ESR1m* serial monitoring into clinical practice in HR+/HER2– metastatic breast cancer, including appropriate timing of ctDNA monitoring tests, patient selection, and implementation of serial monitoring strategies

AGENDA:

TIME (BRT)	TOPIC	SPEAKER
13:00 – 13:05	Welcome & introduction	Dr. Stephen Chia University of British Columbia / BC Cancer, Vancouver Cancer Centre, Canada
13:05 – 13:25	Evolving evidence on <i>ESR1m</i> in HR+/HER2- metastatic breast cancer management	Dr. Stephen Chia University of British Columbia / BC Cancer, Vancouver Cancer Centre, Canada
13:25 – 13:45	Practical considerations for <i>ESR1m</i> testing	Prof. Dr. Kanay Yazarbaş Prof. Dr. Kanay Yazarbaş Florence Nightingale Hospital, Istanbul, Türkiye
13:45 – 14:05	Integrating <i>ESR1m</i> serial testing into clinical practice	Dr. Renata Bonadio Instituto do Câncer do Estado de São Paulo (ICESP), Brazil
14:05 – 14:25	Discussion and Q&A	Chair & All Participants
14:25 – 14:30	Key Take-home Messages & Closing Remarks	Dr. Stephen Chia University of British Columbia / BC Cancer, Vancouver Cancer Centre, Canada

Abbreviations: ctDNA, circulating tumor DNA; *ESR1*, estrogen receptor 1; *ESR1m*, estrogen receptor 1 mutation(s); HR+/HER2–, hormone receptor-positive/human epidermal growth factor receptor 2-negative

If you are interested in participating in this educational webinar, please register via the link below:

Registration Link

We look forward to your participation and hope you will find this session informative and valuable for your clinical practice.

Proprietary and confidential © AstraZeneca 2026. Not for further distribution. This Non-Promotional Educational Webinar is organized and funded by AstraZeneca for invited healthcare professionals (HCPs) only. This is a personal, non-transferable invitation. This event is intended for healthcare professionals who prescribe or dispense medications. VEEVA ID: BR-53851 | DOP: August 2026



Champion



Siga a AstraZeneca nas redes sociais!